Should we have any doubts about hypertension therapy in elderly patients? ACCF/AHA 2011 expert consensus document on hypertension in the elderly

Polskie Archiwum Medycyny Wewnetrznej

Volumn 121, Issue 7-8, 2011, Pages 253-257

  Banach, Maciej ^a   Aronow, Wilbert S ^b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Blood pressure; Elderly; Hypertension; Management; Therapy

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BODY WEIGHT; CARDIOVASCULAR RISK; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG TOLERABILITY; ELDERLY CARE; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; PRACTICE GUIDELINE; REVIEW; SODIUM RESTRICTION; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

EID: 80052379818     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1069     Document Type: Review

References (30)

1. Mancia G., Laurent S., Agabiti-Rosei E., et al.; European Society of Hypertension. Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document. J Hypertens. 2009; 27: 2121-2158.
2. Banach M., Rysz J. Current problems in hypertension and nephrology. Expert Opin Pharmacother. 2010; 11: 2575-2578.
3. Banach M., Kjeldsen S.E., Narkiewicz K. Controversies in hypertension treatment. Curr Vasc Pharmacol. 2010; 8: 731-732.
4. Banach M., Michalska M., Kjeldsen S.E., et al. What should be the optimal levels of blood pressure: Does the J-curve phenomenon really exist? Expert Opin Pharmacother. 2011; 12: 1835-1844.
5. Banach M., Bhatia V., Feller M.A., et al. Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure. Am J Cardiol. 2011; 107: 1208-1214.
6. Aronow W.S. Commentary on implications of new hypertension guidelines in the United States. Hypertension. 2011. In press.
7. Bielecka-Dabrowa A., Aronow W.S., Rysz J., Banach M. The rise and fall of hypertension: Lessons learned from Eastern Europe. Curr Cardiovasc Risk Rep. 2011; 5: 174-179.
8. Aronow W.S. Office management of hypertension in older persons. Am J Med. 2011; 124: 498-500.
9. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA. 2003; 289: 2560-2572. (Pubitemid 37430158)
10. Sethi A., Arora R.R. Ambulatory blood pressure as a predictor of cardiovascular risk. Arch Med Sci. 2009; 5: 3-9.
11. Shah T., Aronow W.S., Peterson S.J., Goldwag D. Diagnosis, treatment, and referral of hypertension or prehypertension in an emergency department after an educational program: Preliminary results. J Clin Hypertens (Greenwich). 2011; 13: 413-415.
12. Aronow W.S. Why and how we should treat elderly patients with hypertension- Curr Vasc Pharmacol. 2010; 8: 780-787.
13. Beckett N.S., Peters R., Fletcher A.E., et al. Treatment of hypertension in patients 80 years of age or older. N Eng J Med. 2008; 358: 1887-1898. (Pubitemid 351620109)
14. Eurostat 2010. A statistical perspective on women and men in the EU27. http://epp.eurostat.ec.europa.eu/cache/ITY-PUBLIC/1-05032010-AP/EN/ 1-05032010-AP-EN.PDF. Accessed May 19, 2011.
15. Leis M., Gijsbers G. Report on Active and Healthy Ageing - A Long-term View up to 2050. Updated with results from the expert workshop on "Active and Healthy Ageing". 31.01.2011. Brussels. European Foresight Platform, 2011.
16. Aronow W.S., Fleg J.L., Pepine C.J., et al.; ACCF Task Force. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2011; 123: 2434-2506.
17. Fleg J.L., Aronow W.S., Frishman W.H. Cardiovascular drug therapy in the elderly: Benefits and challenges. Nat Rev Cardiol. 2011; 8: 13-28.
18. Lopez A.D., Mathers C.D., Ezzati M., et al. Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet. 2006; 367: 1747-1757. (Pubitemid 43767064)
19. Lloyd-Jones D., Adams R., Carnethon M., et al. Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009; 119: e21-181.
20. Aronow W.S., Ahmed M.I., Ekundayo O.J., et al. A propensity-matched study of the association of peripheral arterial disease with cardiovascular outcomesin community-dwelling older adults. Am J Cardiol. 2009; 103: 130-135.
21. Banach M., Aronow W.S. Hypertension therapy in the elderly - Do we know the answers to all the questions? The status after publication of the ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. J Hum Hypertens. 2011. In press.
22. Vulic D., Loncar S., Krneta M., et al. Risk factor control and adherence to treatment in patients with coronary heart disease in the Republic of Srpska, Bosnia and Herzegovina in 2005-2006. Arch Med Sci. 2010; 6: 270-275.
23. Gandelman G., Aronow W.S., Varma R. Prevalence of adequate blood pressure control in self-pay or Medicare patients versus Medicaid or private insurance patients with systemic hypertension followed in a university or general medicine clinic. Am J Cardiol. 2004; 94: 815-816. (Pubitemid 39221512)
24. Ga̧sowski J., Tikhonoff V., Stolarz-Skrzypek K., et al. Treatment of hypertension in the elderly in 2010 - A brief review. Expert Opin Pharmacother. 2010; 11: 2609-2617.
25. Szucs T.D., Waeber B., Tomonaga Y. Cost-effectiveness of antihypertensive treatment in patients 80 years of age or older in Switzerland: An analysis of the HYVET study from a Swiss perspective. J Hum Hypertens. 2010; 24: 117-123.
26. Lubas A., Zelichowski G., Prochnicka A., et al. Renal vascular response to angiotensin II inhibition in intensive antihypertensive treatment of essential hypertension. Arch Med Sci. 2010; 6: 533-538.
27. Bielecka-Dabrowa A., Aronow W.S., Rysz J., Banach M. Current place of beta-blockers in the treatment of hypertension. Curr Vasc Pharmacol. 2010; 8: 733-741.
28. Matsuzaki M., Ogihara T., Umemoto S., et al.; Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: A randomized controlled trial. J Hypertens. 2011; 29: 1649-1659.
29. SPRINT trial. Clinicaltrials.gov: http://www.clinicaltrials.gov/ct2/show/ NCT01 206 062. Accessed June 17, 2011.
30. Ogihara T., Saruta T., Rakugi H., et al.; Valsartan in Elderly Isolated Systolic Hypertension Study Group. Target blood pressure for treatment of isolated systolic hypertension in the elderly: Valsartan in elderly isolated systolic hypertension study. Hypertension. 2010; 56: 196-202.